Mankind Pharma Limited (MANKIND) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 25, 2026 3 min read

Mankind Pharma prepares to report its Q1 FY 2026-2027 results, marking the first full quarter of consolidated operations following the acquisition of Bharat Serums and Vaccines. Investors will be focused on how this specialty biologics integration influences margin trajectory and whether the domestic branded portfolio continues to outpace broader industry growth.

Quick Details

Results date	July 30, 2026
Quarter	Q1 FY 2026-2027
Market cap	Rs. 103,546.35 Cr
CMP	Rs. 2,507.2

Mankind Pharma Limited Q1 Results Date and Time

The board meeting is scheduled for July 30, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.

What to expect from Mankind Pharma Limited's Q1 FY27 results

Mankind Pharma's revenue growth is expected to track ahead of the Indian Pharmaceutical Market's 10.3% YoY value growth, supported by the full-quarter consolidation of the Bharat Serums and Vaccines acquisition. Gross margins are likely to remain stable or show marginal expansion, as the high-margin biologics and injectables portfolio from the recent acquisition offsets any pricing headwinds from the 0.65% WPI-linked ceiling price adjustment. However, PAT growth may lag revenue gains, as the company absorbs the full-quarter impact of intangible amortisation and interest costs related to the acquisition-linked borrowings. Management's focus remains on leveraging its large medical representative force to drive specialty therapy penetration, even as increased R&D investment and integration overheads weigh on EBITDA margins.

Key Things To Watch

BSV integration and revenue contribution: Tracking the first full quarter of consolidated performance following the acquisition.

Assessment of the accretion trajectory for the gynaecology and injectables segments.
Management commentary on the revenue contribution from the newly integrated specialty biologics portfolio.

Domestic market performance: Evaluating growth relative to broader industry benchmarks.

Comparison of domestic branded formulations growth against the 10.3% IPM value growth reported in April 2026.
Update on the chronic portfolio's outperformance ratio, which narrowed to 1.1x in FY26.

Financial leverage and costs: Monitoring the impact of acquisition-related debt and operational expenses.

Interest cost run-rate following the Rs. 13,770-crore acquisition of Bharat Serums and Vaccines.
Impact of increased R&D spend and MR force expansion on EBITDA margin stability.

Frequently Asked Questions

How did the Bharat Serums and Vaccines acquisition impact Mankind Pharma's balance sheet?

The acquisition involved a Rs. 13,770-crore investment, leading to increased acquisition-related borrowings on the balance sheet as of March 31, 2026. Q1 will be the first full quarter reflecting the resulting interest costs and intangible amortisation charges.

What is the expected impact of NPPA price controls on this quarter's margins?

The impact is expected to be minimal, as the annual WPI-linked ceiling price revision for scheduled formulations was a marginal 0.65%. No mid-quarter NLEM additions or significant price cuts were identified for the April–June 2026 period.

Is Mankind Pharma's domestic business growing faster than the overall market?

The company's domestic branded formulations business historically outperforms the Indian Pharmaceutical Market, though the chronic portfolio's outperformance ratio narrowed to 1.1x in FY26. Management is expected to discuss whether this momentum continued against the IPM's 10.3% value growth in April 2026.